Atara Biotherapeutics Inc (FRA:AT2)
€ 0.5536 -0.047 (-7.83%) Market Cap: 67.59 Mil Enterprise Value: 76.78 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Atara Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:30PM GMT
Release Date Price: €14.49 (-2.79%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

All righty. So welcome to the Thursday morning of the JPMorgan Health Care Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Atara Bio. And presenting on behalf of the company is CEO, Pascal Touchon. Pascal?

Pascal Touchon
Atara Biotherapeutics, Inc. - President, CEO & Director

Thank you, Anupam. Good morning, everyone. It's my pleasure today to present, on behalf of Atara Bio, our progress over the last few months, as well as our strategies and key milestones for 2020 and beyond. I'm Pascal Touchon, the President and CEO of Atara Bio. Let you read, of course, the forward-looking statements because this presentation and the oral presentation contains forward-looking statements that are made pursuant to the safe harbor provision.

What is very important for us at Atara Bio is about patients. We are here to deliver to these patients' therapies

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot